Organogenesis Holdings (ORGO) Long-Term Deferred Tax (2017 - 2026)

Organogenesis Holdings' Long-Term Deferred Tax history runs 10 years deep, the most recent figure standing at $45.3 million for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 11.31% year-over-year to $45.3 million in Q1 2026; TTM through Mar 2026 was $45.3 million, a 11.31% increase from a year earlier, with the FY2025 full-year figure at $30.0 million, down 24.07% from the prior year.
• Long-Term Deferred Tax rose to $45.3 million in Q1 2026 per ORGO's latest filing, from $30.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $45.6 million in Q3 2025 and bottomed at $28.0 million in Q4 2023.
• The 5-year median for Long-Term Deferred Tax is $32.0 million (2022), against an average of $34.4 million.
• Across the five-year window, Long-Term Deferred Tax soared 177644.44% in 2022 and fell 24.07% in 2025, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $30.0 million in 2022, then decreased by 6.7% to $28.0 million in 2023, then jumped by 40.93% to $39.5 million in 2024, then decreased by 24.07% to $30.0 million in 2025, then jumped by 51.3% to $45.3 million in 2026.
• Per Business Quant, the three latest ORGO Long-Term Deferred Tax figures stand at $45.3 million (Q1 2026), $30.0 million (Q4 2025), and $45.6 million (Q3 2025).